Seven US senators from both parties said the Trump administration's decision to authorize Russian diesel imports conflicts with a 2022 law banning Russian energy imports and accused it of failing to consult Congress, in a statement on 11 October.
The dispute comes as the war with Iran drives up US fuel prices, which US President Donald Trump has blamed on Ukraine's strikes on Russian refineries. Trump says Russian supplies will help bring prices down, while lawmakers warn that purchases could provide Moscow with revenue to continue its war against Ukraine.
The senators—Republicans Susan Collins, Lisa Murkowski, Thom Tillis, and John Curtis, and Democrats Jeanne Shaheen, Richard Blumenthal, and Ron Wyden—called on the administration to reverse course, saying the US should not provide Russian President Vladimir Putin with “a financial lifeline.”
The law, signed on 8 April 2022, allows the president to end the import ban only after submitting a certification to Congress. The certification must find that Russia has agreed to pull out its forces and stop the fighting on terms Ukraine's free and independent government accepts, no longer poses an immediate threat of attack to any NATO member, and recognizes Ukrainians' right to pick their own government.
The law also requires consultation with four congressional committees and a report at least 45 days before certification. The termination takes effect 90 days after certification unless a joint resolution of disapproval is enacted into law during that period. The senators allege the administration failed to meet the consultation and reporting requirements. Their statement does not establish whether a certification has been submitted.
The Treasury Department's Office of Foreign Assets Control issued General License No. 135 on 9 October, authorizing certain transactions involving Russian-origin diesel that would otherwise be restricted under US sanctions regulations. It runs until 7 April 2027 and cites sanctions regulations, not the 2022 import-ban law.
Treasury Secretary Scott Bessent defended the deal on Fox News on 11 October, saying the administration would proceed under existing legal authority. He said lawmakers who argued that either the earlier law or the current Lindsey Graham sanctions law prohibited the deal were wrong, and argued the agreement would lower prices, Reuters reported.
Trump said on Truth Social that Russia would immediately supply more than 300,000 tons of diesel to US and global markets, followed by 500,000 tons in November and 1 million tons after that. He said Russia would deliver another 3 million tons “within a short period of time,” depending on the condition of its diesel refineries. The promised volumes have not been independently verified.
Russia partially lifted its diesel export ban on 10 October, allowing 500,000 tons onto the global market at this stage, the Russian government said, according to state news agency TASS.
Pennsylvania Republican Rep. Brian Fitzpatrick plans to introduce the Ronald Reagan Peace Through Strength Act to block Russian oil purchases and use a discharge petition to force a House vote, Axios reported. The procedure can force consideration of a bill if 218 House members sign. Republican Rep. Don Bacon said he would support the bill and called Trump's decision a serious mistake, according to Ukrainska Pravda.
On CBS's Face the Nation on 11 October, Senate Majority Whip John Barrasso, a Republican from Wyoming, called the deal “another point of leverage” for Trump to use against Putin. Asked whether the decision violated US law, Barrasso said the president was balancing competing priorities and had to make tough decisions.
Ukrainian President Volodymyr Zelenskyy wrote on Telegram on 9 October:
“Allowing Russia to sell petroleum products is an investment in a war that must be ended, not prolonged.”
Trump also expects Ukraine to stop striking Russian refineries under his proposed energy ceasefire, a White House official told Axios. Zelenskyy said Kyiv would halt such strikes if Moscow did the same.
This year's European Society of Cardiology (ESC) Congress showed just how quickly cardiology is changing. Late-breaking trials, new scientific data and major guideline updates all pointed to a field that is becoming both more crowded and more complex.
A central question the conference sought to address was how effectively the two main types of ATTR-CM treatment work. Stabilizers are designed to prevent the transthyretin protein from breaking apart, while silencers reduce its production. The debate centered on whether silencers offer enough additional benefit over established stabilizers in this significant rare disease market.
One of the clearest lessons was that the challenge is no longer simply bringing more treatments to market. It is increasingly about finding the right patients earlier, understanding how different therapies compare and deciding where each option fits as standards of care improve. ATTR-CM was one of the strongest examples of that shift, with the conference data sharpening the debate over whether silencers offer enough additional benefit over established stabilizers. The same pattern could also be seen in new guidelines and in the growing role of digital monitoring.
Alnylam Pharmaceuticals came to ESC looking to strengthen the case for Amvuttra in ATTR-CM, but the data arguably leave some important questions unanswered. While the drug is already approved, the estimated benefit appeared more modest than many investors and clinicians may have hoped, particularly given the growing expectation that newer therapies will need to demonstrate clear advantages over established treatments. The key question is whether ATTR-CM silencer treatments offer enough additional benefit on top of stabilizers that are already delivering meaningful clinical outcomes.
In light of this, there remains uncertainty around the extent of Amvuttra's value and whether it will be sufficient to secure a strong position in an increasingly competitive market. The FDA's decision earlier this year to challenge Alnylam's survival claims based on an open-label extension of HELIOS-B only adds to the need for caution. It is, therefore, perhaps unsurprising that Alnylam's share price has come under pressure and that questions are being raised about the long-term commercial viability of Amvuttra in ATTR-CM.
Rather than definitively strengthening the case for Amvuttra, Alnylam's participation at ESC suggests that important questions remain about the true scale of its advantage and whether the evidence is sufficient to establish a clear benefit over existing treatments.
In perhaps a similar spirit, AstraZeneca and Ionis used ESC to revisit the results of the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen), another potential treatment for ATTR-CM. They faced a somewhat different challenge, however, as the trial had already failed its primary endpoint, with Wainua unable to significantly reduce cardiovascular mortality and recurrent cardiovascular events in the overall study population.
The companies sought to contextualize the findings, but the presentation arguably highlighted one of the trial's central challenges. If the apparent benefit is less clear among patients already receiving stabilizer therapy, the data raise broader questions about how much additional value silencers can deliver beyond treatments that are already producing meaningful clinical outcomes. The broader question, however, is what this means for an ATTR-CM market that is becoming increasingly competitive. As new treatments emerge, should attention shift towards newer therapies, or remain focused on established stabilizers that may already be providing much of the available benefit?
ESC also saw the release of new guidelines that could change how cardiovascular patients are identified and managed. The updated heart failure guidance simplifies how patients are classified and puts more focus on prevention and earlier intervention. In practice, that means clinicians may be looking for risk earlier and across a broader group of patients, rather than waiting until disease is more advanced.
That change is creating more room for digital tools. Huawei used ESC to preview its Watch D3, a wrist-based ambulatory blood pressure monitor designed to track blood pressure in everyday settings. It is one example of how wearables are moving beyond basic wellness tracking and towards data that could help identify risk earlier, monitor patients more closely and support treatment decisions.
Reflecting on ESC 2026, ATTR-CM emerged as a key area of focus. The AstraZeneca and Alnylam data raised questions about whether silencers can offer enough benefit over established stabilizers, while new guidelines and digital tools highlighted the importance of identifying risk earlier and monitoring patients more closely. The key question now, arguably, is which approaches can genuinely improve on what is already available, and which patients are most likely to benefit.
Login